Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: It can be a specific marker for Lewy body disease

Annals of Nuclear Medicine

Volumn 18, Issue 6, 2004, Pages 453-461

  Taki, Junichi ^a   Yoshita, Mitsuhiro ^a   Yamada, Masahito ^a   Tonami, Norihisa ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

123I MIBG; Dementia with Lewy bodies; Lewy body disease; Multiple system atrophy; Parkinson's disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANGIOTENSIN; DOPAMINE; FLUORINE 18; GUANETHIDINE; NORADRENALIN; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADRENERGIC SYSTEM; AKINESIA; ALZHEIMER DISEASE; AUTONOMIC DYSFUNCTION; BRADYKINESIA; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DOPAMINERGIC NERVE CELL; DRUG UPTAKE; HEART DENERVATION; HUMAN; NEUROPATHOLOGY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; RIGIDITY; SCINTIGRAPHY; SHY DRAGER SYNDROME; TREMOR; ANIMAL; AUTONOMIC NERVOUS SYSTEM; BRAIN; CLINICAL TRIAL; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; ANIMALS; AUTONOMIC NERVOUS SYSTEM; BRAIN; CLINICAL TRIALS; HUMANS; LEWY BODY DISEASE; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; RADIOPHARMACEUTICALS;

EID: 6944237005     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02984560     Document Type: Review

References (72)

1. Taki J, Nakajima K, Bunko H, Simizu M, Muramori A, Hisada K. Whole-body distribution of iodine 123 metaiodobenzylguanidine in hypertrophic cardiomyopathy: significance of its washout from the heart. Eur J Nucl Med 1990; 17: 264-268.
2. Matsunari I, Bunko H, Taki J, Nakajima K, Muramori A, Kuji I, et al. Regional uptake of iodine- 125-metaiodobenzylguanidine in the rat heart. Eur J Nucl Med 1993; 20: 1104-1107.
3. 123I-MIBG uptake and increased clearance in various cardiac diseases. Nucl Med Commun 1994; 15: 317-323.
4. 123I]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM. Comparison with cardiovascular reflex tests and relationship to left ventricular function. Diabetes 1995; 44: 543-549.
5. Langer A, Freeman MR, Josse RG, Armstrong PW. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol 1995; 25: 610-618.
6. Sakata K, Shirotani M, Yoshida H, Kurata C. Iodine-123 metaiodobenzylguanidine cardiac imaging to identify and localize vasospastic angina without significant coronary artery narrowing. J Am Coll Cardiol 1997; 30: 370-376.
7. Tamaki N, Tadamura E, Kudoh T, Hattori N, Inubushi M, Konishi J. Recent advances in nuclear cardiology in the study of coronary artery disease. Ann Nucl Med 1997; 11: 55-66.
8. Matsunari I, Schricke U, Bengel FM, Haase HU, Barthel P, Schmidt G, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation 2000; 101: 2579-2585.
9. 123I-MIBG SPECT imaging. Ann Nucl Med 2000; 14: 333-337.
10. 123I-MIBG scintigraphic and echocardiographic data. Ann Nucl Med 2000; 14: 427-432.
11. Sakata K, Yoshida H, Nawada R, Obayashi K, Tamekiyo H, Mochizuki M. Scintigraphic assessment of regional cardiac sympathetic nervous system in patients with single-vessel coronary artery disease. Ann Nucl Med 2000; 14: 151-158.
12. Koyama K, Inoue T, Hasegawa A, Oriuchi N, Okamoto E, Tomaru Y, et al. Alternating myocardial sympathetic neural function of athlete's heart in professional cycle racers examined with iodine-123-MIBG myocardial scintigraphy. Ann Nucl Med 2001; 15: 307-312.
13. Matsuo S, Nakamura Y, Matsui T, Matsumoto T, Kinoshita M. Detection of denervated but viable myocardium in cardiac sarcoidosis with I-123 MIBG and Tl-201 SPECT imaging. Ann Nucl Med 2001; 15: 373-375.
14. 123I-MIBG myocardial scintigraphy in non-insulin-dependent diabetes mellitus. Ann Nucl Med 2002; 16: 33-38.
15. Narula J, Zaret BL. Epilogue: development of novel imaging techniques for ultimately superior management of congestive heart failure. J Nucl Cardiol 2002; 9: 81S-86S.
16. Shimizu M, Ino H, Yamaguchi M, Terai H, Hayashi K, Nakajima K, et al. Heterogeneity of cardiac sympathetic nerve activity and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Nucl Med 2002; 43: 15-20.
17. 123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 1994; 49: 81-84.
18. Ando Y, Obayashi K, Tanaka Y, Tsuji T, Uchino M, Takahashi M, et al. Radiolabelled metaiodobenzylguanidine in assessment of autonomic dysfunction. Lancet 1994; 343: 984-985.
19. Francis GS. Modulation of peripheral sympathetic nerve transmission. J Am Coll Cardiol 1988; 12: 250-254.
20. Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981; 22: 22-31.
21. Nakajo M, Shimabukuro K, Yoshimura H, Yonekura R, Nakabeppu Y, Tanoue P, et al. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med 1986; 27: 84-89.
22. Tobes MC, Jaques S Jr, Wieland DM, Sisson JC. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med 1985; 26: 897-907.
23. Dae MW, De Marco T, Botvinick EH, O'Connell JW, Hattner RS, Huberty JP, et al. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts-implications for clinical studies. J Nucl Med 1992; 33: 1444-1450.
24. Fagret D, Wolf JE, Vanzetto G, Borrel E. Myocardial uptake of metaiodobenzylguanidine in patients with left ventricular hypertrophy secondary to valvular aortic stenosis. J Nucl Med 1993; 34: 57-60.
25. Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987; 28: 1625-1636.
26. Manger WM, Hoffman BB. Heart imaging in the diagnosis of pheochromocytoma and assessment of catecholamine uptake. J Nucl Med 1983; 24: 1194-1196.
27. Glowniak JV, Turner FE, Gray LL, Palac RT, Lagunas-Solar MC, Woodward WR. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med 1989; 30: 1182-1191.
28. Sisson JC, Bolgos G, Johnson J, Measuring acute changes in adrenergic nerve activity of the heart in the living animal. Am Heart J 1991; 121: 1119-1123.
29. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996; 93: 1667-1676.
30. Riess O, Kruger R, Schulz JB. Spectrum of phenotypes and genotypes in Parkinson's disease. J Neurol 2002; 249 Suppl 3: III/15-20.
31. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752.
32. Takahashi H, Wakabayashi K. The cellular pathology of Parkinson's disease. Neuropathology 2001; 21: 315-322.
33. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002; 249 Suppl 3: III/1-5.
34. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
35. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003; 110: 517-536.
36. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997; 38 Suppl 2: 2-7.
37. Wakabayashi K, Takahashi H, Ohama E, Takeda S, Ikuta F. Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. Adv Neurol 1993; 60: 609-612.
38. Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H, et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 1999; 52: 1269-1271.
39. Orimo S, Ozawa E, Oka T, Nakade S, Tsuchiya K, Yoshimoto M, et al. Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology 2001; 57: 1140-1141.
40. Orimo S, Oka T, Miura H, Tsuchiya K, Mori F, Wakabayashi K, et al. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry 2002; 73: 776-777.
41. 123I-meta-iodobenzyl guanidine in Parkinson's disease. Nucl Med Commun 1998; 19: 137-142.
42. Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 2000; 27: 566-573.
43. Takatsu H, Nishida H, Matsuo H, Watanabe S, Nagashima K, Wada H, et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med 2000; 41: 71-77.
44. Druschky A, Hilz MJ, Platsch G, Radespiel-Troger M, Druschky K, Kuwert T, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 2000; 175: 3-12.
45. 123I-MIBG uptake in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74: 423-426.
46. 123I]iodobenzylguanidine in Parkinson's disease with autonomic failure. Acta Neurol Scand 1998; 97: 307-314.
47. 123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999; 53: 1020-1025.
48. 123)I- metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67: 189-194.
49. Courbon F, Brefel-Courbon C, Thalamas C, Alibelli MJ, Berry I, Montastruc JL, et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord 2003; 18: 890-897.
50. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998; 155: 60-67.
51. 123I-MIBG uptake in Parkinson's disease. Acta Neurol Scand 1998; 97: 303-306.
52. 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 1999; 40: 371-375.
53. Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, Cannon RO, 3rd. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 2000; 133: 338-347.
54. Eisenhofer G, Esler MD, Meredith IT, Dart A, Cannon RO 3rd, Quyyumi AA, et al. Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine. Circulation 1992; 85: 1775-1785.
55. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 672-681.
56. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42: 1142-1146.
57. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
58. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140-148.
59. Wenning GK, Litvan I, Jankovic J, Granata R, Mangone CA, McKee A, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998; 64: 184-189.
60. Reinhardt MJ, Jungling FD, Krause TM, Braune S. Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake. Eur J Nucl Med 2000; 27: 595-600.
61. Takatsu H, Nagashima K, Murase M, Fujiwara H, Nishida H, Matsuo H, et al. Differentiating Parkinson disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA 2000; 284: 44-45.
62. Jellinger K, Riederer P, Tomonaga M. Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm Suppl 1980: 111-128.
63. Wenning GK, Ebersbach G, Verny M, Chaudhuri KR, Jellinger K, McKee A, et al. Progression of falls in postmortem-confirmed parkinsonian disorders. Mov Disord 1999; 14: 947-950.
64. 123I] meta-iodobenzylguanidine myocardial scintigraphy differentiates corticobasal degeneration from Parkinson's disease. Intern Med 2003; 42: 127-128.
65. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. Lancet Neurol 2004; 3: 19-28.
66. McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 1999; 53: 902-905.
67. 123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2001; 71: 583-588.
68. 123)I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 70: 781-783.
69. 123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer's disease and dementia with Lewy bodies. Intern Med 2003; 42: 686-690.
70. Hishikawa N, Hashizume Y, Yoshida M, Sobue G. Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol (Berl) 2003; 105: 341-350.
71. 123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 1995; 53: 230-234.
72. 123I-MIBG scintigraphy in pure progressive autonomic failure. Eur Neurol 1997; 38: 291-296.